| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0022-3476(05)81668-3 |
| P698 | PubMed publication ID | 2295956 |
| P2093 | author name string | A R Perez-Atayde | |
| S E Lipshultz | |||
| A M Goorin | |||
| J Cruz | |||
| A R Chauvenet | |||
| R McKone | |||
| P2860 | cites work | Risk factors for doxorubicin-induced congestive heart failure | Q28328220 |
| The cardiotoxicity of adriamycin and daunomycin in children | Q28341976 | ||
| Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review | Q39729099 | ||
| Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children | Q42261406 | ||
| Echocardiographic measurements in normal subjects. Growth-related changes that occur between infancy and early adulthood | Q52798870 | ||
| Cardiopulmonary Function in Long-Term Survivors of Childhood Hodgkin's Lymphoma: A Pilot Study | Q68296263 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| chemotherapy | Q974135 | ||
| childhood cancer | Q5097977 | ||
| congestive heart failure | Q19000661 | ||
| P304 | page(s) | 144-147 | |
| P577 | publication date | 1990-01-01 | |
| P1433 | published in | The Journal of Pediatrics | Q7743611 |
| P1476 | title | Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer | |
| P478 | volume | 116 |
| Q40470673 | Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study. |
| Q34626238 | Anthracycline-associated cardiotoxicity in survivors of childhood cancer |
| Q36116430 | Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management |
| Q37421187 | Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron |
| Q33613628 | Anthracyclines and the heart |
| Q33625243 | Anthracyclines: cardiotoxicity and its prevention |
| Q33336217 | Cardiac damage after treatment of childhood cancer: a long-term follow-up |
| Q43807501 | Cardiotoxicity After Anthracycline Treatment in Survivors of Adult Cancers: Monitoring by USCOM, Echocardiography and Serum Biomarkers |
| Q33852542 | Cardiotoxicity of doxorubicin and other anthracycline derivatives |
| Q35934224 | Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis |
| Q34700590 | Defective osteogenic differentiation in the development of osteosarcoma |
| Q33806580 | Developing strategies for long term follow up of survivors of childhood cancer |
| Q36944395 | Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. |
| Q77626191 | Discriminative ability of conventional echocardiography and tissue Doppler imaging techniques for the detection of subclinical cardiotoxic effects of treatment with anthracyclines |
| Q40304250 | Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model |
| Q72257340 | Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters |
| Q83867204 | Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer |
| Q68289938 | Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy |
| Q73082939 | Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood |
| Q35757419 | Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood |
| Q42556966 | Late cardiotoxicity after treatment for a malignant bone tumor |
| Q71975481 | Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress |
| Q70978687 | Late effects of treatment for Wilms tumor |
| Q33691101 | Late effects of treatment for wilms tumor |
| Q74607086 | Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood |
| Q41586639 | Long-term survivors of childhood cancer. The medical consequences of cure |
| Q36115135 | Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. |
| Q38588243 | Molecular basis of differentiation therapy for soft tissue sarcomas |
| Q46951554 | Myocardial strain analysis in a doxorubicin-induced cardiomyopathy model. |
| Q36552392 | New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. |
| Q36568908 | Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. |
| Q55118422 | Pregnancy and Cardiomyopathy After Anthracyclines in Childhood. |
| Q37671241 | Principles of treatment of pediatric solid tumors |
| Q79092702 | Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy |
| Q37166807 | Remaining problems in the treatment of patients with Wilms' tumor. |
| Q26828577 | Renal tumours: long-term outcome |
| Q43648912 | Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group |
| Q41114986 | Toxicity of chemotherapy |
| Q39759252 | Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence |
| Q40734980 | Ventricular dysfunction clinical research in infants, children and adolescents |
| Q77708592 | Ventricular repolarization time indexes following anthracycline treatment |
| Q74603959 | [Heart pathology of extracardiac origin. VII. Heart and neoplasms] |
Search more.